Cancer Biodetection Dogs and the In Situ Foundation

The Research Premise

Cancers produce volatile organic compounds — VOCs — that can be present in patient breath, urine, blood, and tissue samples at very low concentrations. The premise of canine cancer biodetection research is that trained dogs can detect these VOC signatures and discriminate between cancer-positive and cancer-negative samples in controlled studies. Decades of research, accelerating significantly since the early 2000s, has produced peer-reviewed sensitivity and specificity data across multiple cancer types.

The honest framing for any reader exploring this topic is critical to state at the outset: canine cancer biodetection is research-stage work. It is not a clinically available diagnostic test. It is not FDA-approved. It is not a replacement for mammography, colonoscopy, low-dose CT, biopsy, or any other standard-of-care diagnostic. The research is genuinely interesting and informs ongoing electronic nose and biosensor development. It is not a screening tool you can use for yourself or your family.

What the Peer-Reviewed Literature Shows

Published studies have examined canine detection of several cancer types from a variety of sample matrices. Penn Vet Working Dog Center and the Monell Chemical Senses Center have collaborated on ovarian cancer detection research using patient tissue and blood samples. Studies in lung cancer detection from patient breath samples have appeared in journals including the European Respiratory Journal. Breast cancer, prostate cancer, colorectal cancer, and bladder cancer have each been the subject of published canine detection research with varying study designs and sample sizes.

Reported sensitivity numbers in some studies run high — sometimes in the 90 percent range for specific protocols on specific sample types. Specificity numbers are also high in many studies. These are encouraging numbers in the research context. They do not translate directly to clinical utility because the studies are typically small, the dogs are working under highly controlled conditions, and the question of whether the methodology scales to population-level screening remains open.

Honest framing of the literature does not require minimizing the encouraging findings. It requires accurate context — the studies are proof-of-concept research, the translation challenges are substantial, and the field has not produced a clinical diagnostic despite two decades of effort.

The Research Organizations

Several organizations and university programs are central to the canine cancer biodetection field. In Situ Foundation, founded by Dina Zaphiris in California, is a nonprofit dedicated to cancer detection dog research. The foundation trains research dogs, publishes findings, and advocates for the broader research field. Penn Vet Working Dog Center at the University of Pennsylvania has been a major contributor through partnerships with Monell Chemical Senses Center and other research collaborators.

Medical Detection Dogs in the United Kingdom, led by Dr. Claire Guest, has published extensively across multiple cancer types and has demonstrated training methodology in a structured research context. Researchers across other US, European, and Asian programs have contributed peer-reviewed work. The field has a recognizable group of contributors and a growing literature base.

For readers who want to understand the broader medical alert and biodetection landscape, the published canine cancer biodetection work sits adjacent to but distinct from clinical medical alert service dogs trained for individual handler tasks — including programs covered in our pieces on diabetic alert dog training and certification and cardiac alert service dog. Those service dogs work with individual patient handlers and ADA-protected tasks; cancer biodetection research dogs work in laboratory and study contexts.

Why It Is Not Clinical Today

The gap between research-stage proof-of-concept and clinical diagnostic deployment is significant. Several specific challenges have not been solved at scale. VOC signatures appear to vary across cancer subtypes, between individuals with the same cancer, between sample types from the same patient, and over time within the same patient. Whether a single trained dog can generalize across this variation reliably enough for clinical use remains unclear.

Training cost and infrastructure is another challenge. Producing a research-grade cancer detection dog requires months of training, structured proofing against false-positive triggers, and ongoing maintenance. Scaling that to the volume needed for population-level screening would require infrastructure that does not currently exist. Even if the science fully supported clinical use, the operational implementation challenge would be enormous.

Regulatory pathways are also not established. FDA does not currently have a framework for approving a trained dog as a clinical diagnostic. Whether that would happen through a medical device pathway, a laboratory test pathway, or something novel is unresolved. Without a regulatory pathway, the research-to-clinic transition has no clear mechanism.

What Cancer Biodetection Research Has Contributed

The research has had real impact even though it has not produced a clinical canine diagnostic. The most important contribution is probably the informing of electronic nose and biosensor development. If dogs can detect cancer VOCs at reliable rates, that suggests the VOCs exist and are sufficient information to discriminate cancer. Electronic nose researchers use this finding to guide their own work — what compounds to target, what sample matrices to use, what discrimination tasks are feasible.

Several electronic nose technologies have emerged that draw on canine biodetection findings. Some are in research and development; some have entered clinical trials. The dogs may not be the diagnostic tool, but they may be pointing the way to a diagnostic tool. This is a meaningful contribution to the broader cancer-detection research enterprise.

The research has also informed canine olfaction science more generally. Studies on cancer biodetection have produced findings about dog odor discrimination capacity, training methodology, and the biology of canine VOC perception that inform other detection disciplines including conservation scat detection, infectious disease detection like COVID-19 biodetection, and even pest detection like bedbug detection.

What This Means for Patients and Families

If you or a loved one is dealing with a cancer diagnosis or screening question, canine biodetection is not a clinical option that should factor into your care decisions. Standard-of-care diagnostic workups — mammography, colonoscopy, low-dose CT for lung cancer in high-risk patients, biopsy, blood-based biomarker testing where validated — are the evidence-based tools. Your oncologist and primary care physician work within that framework.

The research on canine biodetection is interesting and may eventually inform new diagnostic tools that benefit patients. Today, it does not. Anyone claiming that they can offer canine cancer screening as a clinical service is operating outside the research-stage frame and outside any current regulatory framework. The honest scientific consensus is that the research is promising and unfinished.

How Research Dogs Are Trained

Research dogs are trained on patient samples sourced under research-ethics protocols with appropriate consent. Samples are typically frozen at collection and presented to dogs in controlled experimental setups — often a sample carousel or scent wheel where the dog moves through positions, indicates the cancer-positive sample, and earns reward. Training imprints the dog on cancer-VOC odor, proofs against control samples, and develops a clean indication.

The studies use various designs. Double-blind protocols, where neither handler nor dog knows which sample is the positive, are essential to credible findings — the Clever Hans effect, where a dog cues off subtle handler signals rather than the sample, is a real risk that good study design controls for. Cross-validation, multiple-dog protocols, and replication across labs add further rigor.

Welfare and Working Conditions

Research detection dog welfare is generally good in well-run programs. The work is engaging — search, indicate, get paid in reward — and the indoor laboratory environment is comfortable. Dogs often work part of the day and live with their handlers or in well-equipped kennel facilities. Programs like Penn Vet Working Dog Center have invested in dog welfare infrastructure and decompression protocols consistent with the broader AVMA and IWDBA working-dog welfare framework.

Where some dogs come from is also welfare-positive. High-drive shelter and rescue dogs are sometimes evaluated into research programs, finding a working career that engages traits that made them difficult pets. The broader working dog washout adoption pipeline overlaps with the talent stream for cancer biodetection research dogs.

The Honest Future

The future of canine cancer biodetection is most likely as a research enterprise that informs other diagnostic technologies rather than as a clinical service in its own right. Electronic noses, biosensor arrays, and other VOC-detection technologies are advancing rapidly and have plausible clinical pathways. Trained dogs will likely remain a research tool that helps define what is detectable and what signatures are worth pursuing in non-canine platforms.

This is not a dismissal of the field. It is the honest scientific framing. The dogs have shown what is possible. The translation to clinical utility, if it happens, will likely happen through technologies that can be standardized, scaled, regulated, and deployed in clinical workflows — none of which are easily achieved with trained dogs.

Frequently Asked Questions

Can I get cancer screening from a trained dog?

No. Canine cancer biodetection is research-stage work. It is not a clinically available diagnostic and is not approved by FDA or any other regulatory body. Anyone offering canine cancer screening as a clinical service is operating outside any current regulatory framework. Evidence-based cancer screening remains the standard-of-care tests your physician orders.

What organizations conduct cancer biodetection research?

In Situ Foundation (founded by Dina Zaphiris), Penn Vet Working Dog Center at the University of Pennsylvania, Medical Detection Dogs in the UK (led by Dr. Claire Guest), and several other university and nonprofit research programs. Monell Chemical Senses Center has been a major collaborator on the analytical chemistry side.

What cancer types have been studied?

Ovarian, lung, breast, prostate, colorectal, bladder, and several other cancers have been the subject of canine biodetection studies. Study sizes vary widely. The literature continues to grow but most studies are proof-of-concept rather than population-level validation.

Will canine cancer detection ever become clinical?

Possibly, but the more likely pathway is that canine research informs electronic nose and biosensor technologies that become clinical. The operational challenges of scaling trained dogs to population-level screening are substantial. The research contribution to other diagnostic technologies may be the field’s most lasting impact.

Where do research detection dogs come from?

Many come from working-dog breeders selected for detection profiles. Some come from shelter and rescue networks where high-drive temperaments are identified and channeled into detection work. The talent stream overlaps with conservation detection and the broader detection-dog ecosystem.